



1642

DOCKET NO: L00461.70066.US


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lethe et al.
Serial No: 09/341,829
Confirmation No: 5643
Filed: October 18, 1999
For: LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS

Examiner: M. Davis
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 17th day of April, 2003.


June Watson

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ Amendment
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If a fee is determined to be required, please charge the balance to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Lethe, et al., Applicant


John R. Van Amsterdam, Reg. No. 40.212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617)720-3500

Docket No. L00461.70066.US
Date: April 17, 2003
x04/20/03

RECEIVED
APR 24 2003
TECH CENTER 1600/2900



DOCKET NO: L00461.70066.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Lethe et al.
Serial No: 09/341,829
Confirmation No: 5643
Filed: October 18, 1999
For: LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS

Examiner: M. Davis
Art Unit: 1642

RECEIVED
APR 22 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 17th day of April, 2003.


June Watson

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action mailed November 20, 2002, please amend the above-identified application as follows:

In the Claims

Applicant presents the claims as amended below and encloses a set of marked-up claims with bracketing and underlining.

Please cancel claim 61 without prejudice or disclaimer.

Please rewrite claims 1, 38, 53, 57 and 58 as indicated below:

1. (twice amended) An isolated nucleic acid molecule selected from the group consisting of

(a) a nucleic acid molecule which hybridizes under highly stringent conditions to a molecule having a nucleotide sequence set forth as SEQ ID NO 4, wherein the isolated nucleic